TICKERNERD
Menu
KRYSKRYSHealthcare · Biotechnology

KRYS Stock Forecast: Krystal Biotech, Inc. Price Predictions for 2026-2027

Last close, 15 Oct 2026
$330
−0.21% on the day

The 12 Wall Street analysts covering Krystal Biotech, Inc. hold a median 12-month price target of $400 — +21.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 77 of 100 as at 14 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$9.5B
Ticker Nerd rank
77 / 100
Median analyst target
$400
Analysts covering
12
Revenue$119.2M+24.1% y/y
Operating income$58.4M
Net income$54.8M
Free cash flow$71.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+0.8%
1M
−2.0%
YTD
+33.9%
1Y
+71.0%
From 52W high
−12.7%
From 52W low
+78.3%
$185
$378
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

KRYS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Krystal Biotech, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Oct 2026
77 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
94
Value
94
Volatility
92
Momentum
89
Growth
61
Issuance
57
Revisions
50
Accruals
30
Size
15

Quality (94): The business earns solid, repeatable profits on what it owns.

Accruals (30): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (15): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

KRYS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on KRYS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$150$200$250$300$350$400$450$500Jan 26Apr 26Jul 26Oct 26KRYSHigh $474Median $400Low $284

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says12 analysts
11 Buy1 Hold0 Sell
Low $284Median $400High $474

The green dot is the last close — the median target sits +21.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
24 Sept 2026Goldman SachsReinstatesBuy$441
21 Sept 2026B of A SecuritiesMaintainsBuy—
21 Sept 2026B of A SecuritiesMaintainsBuy$392 → $400
14 Aug 2026RBC CapitalInitiatesOutperform$400
14 Aug 2026RBC CapitalInitiatesOutperform—
4 Aug 2026CitigroupMaintainsBuy$378 → $386
4 Aug 2026CitigroupMaintainsBuy—
14 July 2026B of A SecuritiesMaintainsBuy$364 → $396
14 July 2026B of A SecuritiesMaintainsBuy—
18 June 2026TD CowenMaintainsBuy—
16 June 2026HC Wainwright & Co.MaintainsBuy—
1 June 2026HC Wainwright & Co.ReiteratesBuy—
22 May 2026HC Wainwright & Co.ReiteratesBuy—
18 May 2026HC Wainwright & Co.ReiteratesBuy—
5 May 2026CitigroupMaintainsBuy—
5 May 2026Evercore ISI GroupMaintainsOutperform—
4 May 2026HC Wainwright & Co.ReiteratesBuy—
27 Mar 2026Wolfe ResearchInitiatesPeer Perform—
25 Feb 2026GuggenheimMaintainsBuy—
18 Feb 2026Chardan CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KRYS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

KRYS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 15 Oct 2026, Krystal Biotech, Inc. returned +71.0% against +17.3% for the S&P 500, dividends included.

KRYS vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180200Jan 26Apr 26Jul 26Oct 26KRYSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

KRYS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−8.6%
Analysts raising
3
Analysts cutting
5
Fundamentals

Krystal Biotech, Inc. (KRYS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
40.2×

Cheaper than 19% of US stocks

Price / sales
21.6×

Cheaper than 8% of US stocks

Price / book
7.0×

Cheaper than 13% of US stocks

EV / EBITDA
45.1×

Cheaper than 6% of US stocks

Growth & margins
Revenue growth (YoY)
24.1%

Higher than 73% of US stocks

Earnings growth (YoY)
42.9%

Higher than 72% of US stocks

Gross margin
94.6%

Higher than 98% of US stocks

Operating margin
49.0%

Higher than 96% of US stocks

Net margin
54.8%

Higher than 97% of US stocks

Returns & dividend
Return on equity
20.1%

Higher than 81% of US stocks

Return on assets
9.4%

Higher than 91% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Krystal Biotech, Inc. (KRYS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Krystal Biotech, Inc. has a market value of $9.5B and an enterprise value of $9.0B.

  • Revenue in the twelve months to 30 June 2026: $440.5M. The latest quarter grew 24.1% year on year.

  • Net income over the same four quarters: $241.5M, a 54.8% net margin.

  • Diluted earnings per share, trailing twelve months: $7.98.

  • Free cash flow in the twelve months to 30 June 2026: $257.8M.

  • Shares outstanding: 29.6M.

  • Trailing P/E: 40.2×; forward P/E: 34.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Krystal Biotech, Inc. employs 295 people — $1.5M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Oct 2026

Data provided by Twelve Data

Peers

KRYS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
KRYSKrystal Biotech, Inc.$9.5B
77
TWSTTwist Bioscience Corp.$9.8B
64
IBRXImmunityBio, Inc.$10.4B
56
MDGLMadrigal Pharmaceuticals, Inc.$10.6B
67
PCVXVaxcyte, Inc.$10.6B
56
BMRNBioMarin Pharmaceutical, Inc.$10.7B
64
KYMRKymera Therapeutics, Inc.$8.9B
74

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Krystal Biotech, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest KRYS news & analysis

Krystal Biotech Announces Positive Clinical Data for New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression in Patients with Gorlin Syndrome

GlobeNewsWire · 15 Oct 2026positive

Krystal Biotech reported initial proof-of-concept data for KB113 in three patients with Gorlin syndrome: more than 80% of assessed basal cell carcinoma lesions regressed, responses included non-injected lesions, and each patient had histologically confirmed clearance of an injected lesion. The company said injections were well tolerated, with reported adverse events mild to moderate and transient.

Why it matters — The update provides early clinical evidence for KRYS’s KB113 dermatology program, including responses beyond directly injected lesions.

Krystal Biotech: My Analysis Suggests Stock Has Not Yet Reached Peak Value

Seeking Alpha · 10 Oct 2026positive

A Seeking Alpha analysis rates Krystal Biotech a “Buy,” citing Vyjuvek sales of $119.2 million in Q2, expanding global reach, profitability, and a promising pipeline. The author also points to a $1.1 billion cash position, a 40% operating margin, and a valuation of about 12 times forward P/E.

Why it matters — The analysis highlights commercial performance, financial resources, and pipeline prospects as factors relevant to KRYS watchers.

Krystal Stock Gains 13.4% in a Month: What Is Driving the Rally?

Zacks Investment Research · 3 Sept 2026positive

Krystal Biotech's stock rose 13.4% over the past month, driven by growth of its product Vyjuvek and its expanding genetic medicine pipeline as the company moves toward multi-product growth, according to Zacks Investment Research.

Why it matters — A KRYS watcher would care because Vyjuvek's continued growth and the expanding pipeline signal the company is progressing toward becoming a multi-product genetic medicine company, a key factor supporting investor confidence.

Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference

GlobeNewsWire · 3 Sept 2026neutral

Krystal Biotech announced it will participate in the 2026 Cantor Global Healthcare Conference on September 10, 2026, in New York. Management will take part in a fireside chat scheduled for 3:55 pm ET and host investor meetings throughout the day.

Why it matters — A KRYS watcher would care because the company's management will have an opportunity to engage with investors and share updates at a major industry conference.

Krystal Biotech (KRYS) Up 12% Since Last Earnings Report: Can It Continue?

Zacks Investment Research · 2 Sept 2026positive

Krystal Biotech reported earnings roughly 30 days ago, and its stock has risen 12% since that report. The article examines whether the company can sustain this upward movement going forward.

Why it matters — KRYS watchers would want to know whether the stock's post-earnings momentum is likely to continue or fade.

FAQ

Frequently asked questions about KRYS stock

What is the KRYS stock price forecast for 2026-2027?

The 12 Wall Street analysts covering Krystal Biotech, Inc. have a median 12-month price target of $400, with estimates ranging from $284 to $474. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is KRYS stock a buy right now?

Of the 12 analysts covering Krystal Biotech, Inc., 11 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Krystal Biotech, Inc. 77 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank KRYS?

As at 14 Oct 2026, Krystal Biotech, Inc. ranks 77 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (94 of 100).

Will KRYS stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +21.2% from the last close, and Ticker Nerd's factor model ranks Krystal Biotech, Inc. 77 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the KRYS stock forecast for 2030?

No analyst covering Krystal Biotech, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KRYS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $284 to $474 over the next 12 months.

How has KRYS stock performed over the past year?

Krystal Biotech, Inc. returned +71.0% over the 12 months to 15 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Krystal Biotech, Inc. do?

Krystal Biotech, Inc. is a commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing genetic medicines for serious and rare diseases.

What is the latest news on KRYS?

The most recent item we track (GlobeNewsWire, 15 Oct 2026): "Krystal Biotech Announces Positive Clinical Data for New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression in Patients with Gorlin Syndrome". Krystal Biotech reported initial proof-of-concept data for KB113 in three patients with Gorlin syndrome: more than 80% of assessed basal cell carcinoma lesions regressed, responses included non-injected lesions, and each patient had histologically confirmed clearance of an injected lesion. The company said injections were well tolerated, with reported adverse events mild to moderate and transient.

Company

About Krystal Biotech, Inc.

Krystal Biotech, Inc. is a commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing genetic medicines for serious and rare diseases. Its lead product, VYJUVEK, is a redosable gene therapy approved for dystrophic epidermolysis bullosa, a rare inherited skin disorder. The company’s work centers on its proprietary HSV-1-based delivery platform, which supports programs across dermatology, respiratory, ophthalmology, oncology, and aesthetics. Through this platform, Krystal Biotech develops therapies designed to address high unmet medical needs and expand treatment options in specialized disease areas. Headquartered in Pittsburgh, Pennsylvania, Krystal Biotech plays a notable role in the gene therapy market by combining commercial operations with a broader pipeline of investigational genetic medicine candidates.

CEO Mr. Krish S. Krishnan M.B.A., M.S. · 295 employees · United States · https://www.krystalbio.com